MGMT and neoplasm: Researchers have developed a systemic nanodelivery platform (scL) for tumor-specific targeting that can deliver WT p53 through the blood–brain barrier, effectively target GBM and cancer stem cells (CSC), downregulate MGMT and induce GBM cell apoptosis.